Î±hydroxylinoleic acid smallmolecule experimental cancer drug developed ability ability announced received orphan drug designation odd pediatric cancer neuroblastoma european medical agency ema us food drug administration also preclinical study confirmed well december company announced odd treatment pancreatic one mechanism action activation ppar receptors gene leading inhibition aktmtor pathway pathway excessively activated human cancers supporting tumor growth principal target various new antitumour drugs tumor cells killed viva autophagy rather activates ppar receptors inducing overexpression binds akt oncogene inhibits aktmtor showed efficacy phase clinical trials patients advanced cancer low toxicity high